The Food and Drug Administration (FDA) has walked back its initial decision last week to decline to review Moderna’s mRNA flu vaccine candidate after holding a high-priority meeting with the company. Last week, the FDA said it had denied Moderna’s filing over regulatory issues. The company said the denial had nothing to do with…
Please follow and like us:
